AngioDynamics (ANGO) reported first quarter earnings of $0.16 per share, which missed analyst estimates. However, the medical device maker’s top line surpassed street consensus. Shares of the company were trading down 8% at 12:22 am ET.
The company reported flat revenues of $85.3 million over last year, hurt by 6% slump in oncology product sales, primarily due to a drop in sales from the radiofrequency ablation line. The company also had a one-time impact in the quarter due to its transition from Acculis to Solero product line.
On the geographic front, AngioDynamics continued last quarter’s trend with US sales dipping nearly 2% over prior year, and international sales growing 7% due to the increased adoption of its products. In the first quarter, the company also paid $12.7 million in lieu of the legal allegations faced with the Justice Department.
Margins improved 380 basis points, touching 52.1% aided by the facility consolidation efforts and improvement in operations. However, free cash flow slipped to the negative territory of $9.5 million compared to a positive cash flow of $2.5 million last year, which remains a concern.
To beef up its oncology portfolio, AngioDynamics acquired RadiaDyne and BioSentry in the quarter, which is expected to boost its bottom line in the upcoming quarters. The company has paid $87 million as upfront consideration, while $43 million as part of earnouts in future.
As a result of the acquisitions, the medical device maker has revised upwards its fiscal 2019 sales outlook, which is expected to come in the range of $354-359 million over $344-349 million guided last quarter. However, adjusted earnings remain unchanged at $0.82-0.86 per share. Shares of the company have jumped above 35% over the last 12 months and up nearly 46% in 2018.
Most Popular
Broadcom (AVGO) reports higher Q3 revenue and profit; results beat estimates
Semiconductor company Broadcom, Inc. (NASDAQ: AVGO) reported higher revenues and adjusted earnings for the third quarter of 2024 amid continued strong demand. The Q3 numbers also topped expectations. Earnings, excluding
Key takeaways from Hewlett Packard’s (HPE) Q3 2024 earnings report
Hewlett Packard Enterprise (NYSE: HPE) has delivered stronger-than-expected third-quarter results amid significant conversion in AI system revenues. The prospects for the company's AI server and edge computing businesses look promising
Hormel Foods (HRL): Factors that put a damper on the food company’s Q3 performance
Shares of Hormel Foods Corporation (NYSE: HRL) were up over 2% on Thursday. The stock is recovering from a fall it took a day ago after the company delivered mixed